International clinical trial for antibody treatment completed
An innovative multicenter study tested an antibody that is directed against the protein Nogo-A, which inhibits nerve fiber growth. The aim is to block nerve regeneration brakes by administering antibodies in order to promote the sprouting of nerve fibers. For this purpose, the Nogo-A antibody was repeatedly injected into the cerebrospinal fluid of high spinal cord injury patients. The so-called 'NISCI' study provides preliminary evidence of a possible improvement in self care (activities of daily living) after antibody administration. Although the targeted extent and thus the so-called ‚primary endpoint‘ was not reached, important conclusions could be drawn. These will be used to focus more specifically on a specific patient group in future testing, which show possible hints for improved function (so-called 'responder group'). This will increase the chance of providing proof of effectiveness.